World J Mens Health.  2023 Jul;41(3):508-537. 10.5534/wjmh.221027.

The British Society for Sexual Medicine Guidelines on Male Adult Testosterone Deficiency, with Statements for Practice

Affiliations
  • 1Department of Urology, Spire Hospital, Little Aston, Birmingham, UK
  • 2Department of Urology, Aston University, Birmingham, UK
  • 3Trends in Urology and Men’s Health, Letchworth, UK
  • 4Faculty of Health & Human Sciences, University of Hertfordshire & The Prostate Centre, London, UK
  • 5Department of Urology, University Hospital Southampton and UCLH, London, UK
  • 6Department of Endocrinology, Barnsley Hospital, Barnsley, UK
  • 7Department of Biochemistry, Royal Hallamshire Hospital, University of Sheffield Medical School, Sheffield, UK
  • 8Division of Surgery and Interventional Science, NIHR Biomedical Research Centre UCLH, London, UK
  • 9Department of Biochemistry, Black Country Pathology Services, Walsall Manor Hospital, Walsall, UK
  • 10Cardiff and Vale NHS Trust, Cardiff, UK
  • 11University of South Wales TDS, Bridgend, UK
  • 12Department of Cardiology, University of Cape Coast, Cape Coast, Ghana
  • 13Portway Surgery, Porthcawl, UK
  • 14Leamington Spa, UK
  • 15Department of Nephrology, NCA, Salford Royal Hospital, Salford, UK
  • 16Department of Clinical Biochemistry, University Hospitals Birmingham NHS Foundation Trust, Sutton Coldfield, West Midlands, UK

Abstract

Testosterone deficiency (TD) is an increasingly common problem with significant health implications, but its diagnosis and management can be challenging. A multi-disciplinary panel from BSSM reviewed the available literature on TD and provide evidence-based statements for clinical practice. Evidence was derived from Medline, EMBASE and Cochrane searches on hypogonadism, testosterone therapy (T Therapy) and cardiovascular safety from May 2017 to September 2022. This revealed 1,714 articles, including 52 clinical trials and 32 placebo-controlled randomised controlled trials. A total of twenty-five statements are provided, relating to five key areas: screening, diagnosis, initiating T Therapy, benefits and risks of T Therapy, and follow-up. Seven statements are supported by level 1 evidence, eight by level 2, five by level 3, and five by level 4. Recent studies have demonstrated that low levels of testosterone in men are associated with increased risk of incident type 2 diabetes mellitus, worse outcomes in chronic kidney disease and COVID 19 infection with increased all-cause mortality, along with significant quality of life implications. These guidelines should help practitioners to effectively diagnose and manage primary and age-related TD.

Keyword

Erectile dysfunction; Hypogonadism; Testosterone deficiency; Testosterone therapy
Full Text Links
  • WJMH
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr